Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Cytomegalovirus Infections

• A Safety Assessment of Oral Letermovir in Infants With Symptomatic Congenital Cytomegalovirus
• Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant Candidates
• Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients
• Efficacy of Letermovir in Preventing Cytomegalovirus (CMV) Infection in Lung Transplant Recipients vs. Valganciclovir.
• A Study of Letermovir (MK-8228) to Evaluate Efficacy and Safety for Prevention of CMV Infection in Chinese Hematopoietic Stem Cell Transplant Recipients (MK-8228-045)
• Effectiveness of an Immune-guided Cytomegalovirus Infection Preventive Strategy Compared to a Universal Prophylactic Strategy in Renal Transplant Patients
• Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients
• CMV CTLs in Neonates With CMV Infection
• Prenatal Treatment of Congenital Cytomegalovirus Infection With Letermovir Versus Valaciclovir
• Efficacy and Safety of Cytotect®CP, Hyperimmune Anti-CMV IVIg as CMV Prophylaxis in Patients Developing Acute Grade II-IV GVHD After Allogeneic Hematopoietic Cell Transplantation.
• R-MVST Cells for Treatment of Viral Infections
• Prevention of Maternal-fetal Cytomegalovirus Transmission After Primary Maternal Infection, GW ≤ 14 (PreCyssion)
• A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy Adults
• Introduction of mTor Inhibitors and the Activation of the Cytomegalovirus (CMV) -Specific Cellular Immune Response
• Association of T Gamma Delta-CD16+ Cells and Anti-CMV Immunoglobulins in the Prevention of CMV Infection
• Comparison of Safety and Efficacy of de Novo Everolimus
• Letermovir Use in Heart Transplant Recipients
• Prenatal Treatment of Congenital Cytomegalovirus Infection With Letermovir Randomized Against Valaciclovir - STEP 1 (CYMEVAL3-STEP1)
• A Study for Kidney Transplant Recipients at High-Risk of Cytomegalovirus Infection
• Treatment of Low Dose IL-2 and Ganciclovir in Cytomegalovirus Infection
• Inflammation and Co-Infections in D²EFT
• MK-8228 (Letermovir) in the Prevention of Human Cytomegalovirus (CMV) Infection and Disease in Adult Japanese Kidney Transplant Recipients (MK-8228-042)
• A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infection
• Extension of Letermovir (LET) From Day 100 to Day 200 Post-transplant for the Prevention of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant (HSCT) Participants (MK-8228-040)
• Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe Pneumonia
• Letermovir Treatment for Refractory or Resistant Cytomegalovirus Infection
• Clinical Trial of Efficacy and Safety of the Combination of Reduced Duration Prophylaxis Followed by Immuno-guided Prophylaxis in Lung Transplant Recipients.
• Pharmacokinetic Parameters of Innovative Valganciclovir Versus Generic Valganciclovir
• Systemic and Topical Antivirals for Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes
• V160 2-Dose and 3-Dose Regimens in Healthy Cytomegalovirus (CMV) Seronegative Females (V160-002)
• Asymptomatic Congenital CMV Treatment
• Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)
• CMV-CTL for the Treatment of CMV Infection After HSCT
• The Strategy in the Prevention of Renal Post-transplant Cytomegalovirus Infection Among Chinese Population
• Topical 2% Ganciclovir Eye Drop for CMV Anterior Uveitis / Endotheliitis
• Study to Evaluate Safety, Tolerability, and Immunogenicity of Candidate Human Cytomegalovirus Vaccine in Healthy Adults
• Sirolimus Associated With Tacrolimus at Low Doses in Elderly Kidney Transplant Patients
• Conversion to Sirolimus: Effects in Cytomegalovirus Infection Recurrence
• Evaluation of the Benefit of Antiviral Treatment With Valganciclovir on Congenital CMV Infection-related Deafness on Hearing and Balance
• Safety, Tolerability, and Immunogenicity of a Cytomegalovirus DNA Vaccine
• Safety and PK of MBX-400 (Cyclopropavir) in Normal Volunteers
• A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus Disease
• A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus
• Valacyclovir to Prevent Vertical Transmission of Cytomegalovirus After Maternal Primary Infection During Pregnancy
• Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporine Versus an Immunosuppressive Regimen With Mycophenolic A
• Letermovir (MK-8228) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001)
• An Evaluation of a Cytomegalovirus (CMV) Vaccine (ASP0113) in CMV-Seropositive and CMV-Seronegative Healthy Subjects and CMV-Seronegative Dialysis Patients
• Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal Transplant
• Congenital Cytomegalovirus: Efficacy of Antiviral Treatment
• ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation
• Evaluation of Early Use of Everolimus (EVE) on Cytomegalovirus (CMV) Infection in Renal Transplant Recipients
• A Study of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Recipients
• Congenital Cytomegalovirus: Efficacy of Antiviral Treatment in a Randomized Controlled Trial
• Valganciclovir Therapy in Infants and Children With Congenital CMV Infection and Hearing Loss
• CMV Modulation of the Immune System in ANCA-associated Vasculitis
• Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
• CMV Antiviral Prevention Strategies in D+R-Liver Transplants ("CAPSIL")
• Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for Cytomegalovirus Infection
• A Study of Oral Valcyte (Valganciclovir) in Pediatric Kidney Transplant Recipients
• A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV)
• Efficacy and Safety of Induction Strategies Combined With Low Tacrolimus Exposure in Kidney Transplant Recipients Receiving Everolimus or Sodium Mycophenolate
• Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant
• A Study on the Pharmacokinetics and Safety of Valcyte (Valganciclovir) in Pediatric Heart Transplant Recipients Less Than 4 Months of Age
• Cytomegalovirus - Immunoprophylactic Adoptive Cellular Therapy Study
• In UTERO Treatment of Cytomegalovirus Congenital Infection With Valacyclovir
• T-Lymphocyte Infusion or Standard Therapy in Treating Patients at Risk of Cytomegalovirus Infection After a Donor Stem Cell Transplant
• Prevention of Transplant Atherosclerosis With Everolimus and Anti-cytomegalovirus Therapy
• Determining a Viral Load Threshold for Treating Cytomegalovirus (CMV)
• Study of CMX001 to Prevent/Control Cytomegalovirus Infection in R+ Hematopoietic Stem Cell Transplant Recipients
• Efficacy Study of Human Cytomegalovirus (HCMV) Hyperimmune Globulin to Prevent Congenital HCMV Infection
• Certican® (Everolimus) Against Cytomegalovirus Disease in Renal Transplant Patients
• Valganciclovir for Treatment of Cytomegalovirus Infection in Solid Organ Transplant Patients
• Measuring Changes in Blood in Patients at High Risk of Cytomegalovirus Infection After Undergoing Donor Bone Marrow Transplant or Peripheral Blood Stem Cell Transplant
• Maribavir Versus Oral Ganciclovir For The Prevention of Cytomegalovirus (CMV) Disease in Liver Transplant Recipients
• Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
• VICTOR Study - A Study of Valcyte (Valganciclovir po) Compared to Ganciclovir iv in Patients With Cytomegalovirus (CMV) Disease Who Are Solid Organ Transplant Recipients
• Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients
• Efficacy and Safety of Valcyte® as an add-on Therapy in Patients With Malignant Glioblastoma and Cytomegalovirus (CMV) Infection
• TAMOVALCIR in Allogenic Hematopoietic Progenitors Transplant
• A Relative Bioavailability Study of Valcyte (Valganciclovir) in Lung Transplant Recipients With or Without Cystic Fibrosis.
• Study of Prophylactic Vs Preemptive Valganciclovir
• Prophylaxis With Ganciclovir Improves Graft Survival in Renal Allograft Recipients
• A Study of Valcyte (Valganciclovir) CMV Prophylaxis After Renal Transplantation
• CMV Glycoprotein B Vaccine in Allograft Recipients
• IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
• Artesunate in Preemptive Treatment of Human Cytomegalovirus (CMV) in Stem Cell Transplant Recipients
• The Study is Being Done to See if Taking the Drug Valganciclovir Can Prevent CMV Infection.
• Ganciclovir Pharmacokinetics in Patients Undergoing Continuous Renal Replacement Therapy
• Valganciclovir to Reduce T Cell Activation in HIV Infection
• Trial of Preemptive Treatment With Oral Valganciclovir Compared With Intravenous (IV) Ganciclovir for Cytomegalovirus Infection After Bone Marrow or Peripheral Blood Stem Cell Transplant
• MICI-CMV:Valganciclovir in Recurrent Bouts of Cryptogenic Inflammatory Bowel Diseases With an Infection by Cytomegalovirus
• Comparison of Oral Valganciclovir and Placebo for the Prevention of Cytomegalovirus (CMV) After Lung Transplantation
• Maribavir for Prevention of CMV After Stem Cell Transplants
• gB/MF59 Vaccine in Preventing Cytomegalovirus Infection in Healthy Adolescent Females
• Recombinant CMV gB Vaccine in Postpartum Women
• A Study of Valcyte (Valganciclovir) Syrup Formulation in Pediatric Solid Organ Transplant Recipients
• Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation
• Valganciclovir to Prevent Cytomegalovirus Infection in Kidney and Kidney/Pancreas Transplant Recipients
• Valganciclovir in Congenital CMV Infants
• Valganciclovir to Prevent Cytomegalovirus Infection in Patients Following Donor Stem Cell Transplantation
• Preventing Cytomegalovirus (CMV) Organ Damage With Valganciclovir in People With HIV
• Phase I/II Study of Human Anti-Cytomegalovirus (CMV) Monoclonal Antibody MSL-109 in Newborns With Symptomatic Congenital CMV Infection Without Central Nervous System Disease
• Kinetics of Response of Cytomegalovirus With Ganciclovir Treatment Using Quantitative Real-Time PCR
• Phase III Randomized, Controlled Study of Ganciclovir for Symptomatic Congenital Cytomegalovirus Infection
• The Safety and Effectiveness of Different Dose Levels of 1263W94 in the Treatment of Cytomegalovirus (CMV) of the Eyes in HIV-Infected Patients
• A Study of Lobucavir in Patients With AIDS
• A Randomized, Phase I/II Trial to Assess the Safety and Antiviral Effects of Escalating Doses of A Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV Viremia and/or Viruria
• A Multiple Dose Crossover Pharmacokinetics Study to Evaluate the Effects of Food on the Absorption of Oral Ganciclovir
• Safety and Efficacy of Intravenous Magnesium Sulfate in Modulating Changes in Symptoms and Divalent Cation Levels Associated With Foscavir Therapy: A Phase IV Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Pilot Study
• A Phase I Pharmacokinetic Study in HIV-Positive Subjects of Oral Ganciclovir and Concomitant Antiretroviral Zidovudine and Didanosine
• A Randomized, Double-Blind Study of the Efficacy and Safety of Oral Ganciclovir for the Prevention of CMV Disease in People Infected With the Human Immunodeficiency Virus
• Open Label Ganciclovir Therapy for Sight- or Life-Threatening Cytomegalovirus Disease in the Immunocompromised Patient
• Ganciclovir: Compassionate Use in Patients With Serious or Life-Threatening Cytomegalovirus Infections
• Effects of Hormone Therapy on the Immune Systems of Postmenopausal Women With Chronic Infections
• A Phase III Study to Evaluate the Safety and Efficacy of Ganciclovir (Dihydroxypropoxymethyl Guanine [DHPG]) Treatment of Symptomatic Central Nervous System (CNS) Congenital Cytomegalovirus (CMV) Infections.
• The Safety and Effectiveness of Adefovir Dipivoxil in the Treatment of HIV-Infected Patients
• A Study of Valacyclovir Hydrochloride in the Prevention of Life-Threatening Cytomegalovirus Disease in HIV-Infected Patients
• A Study of AZT Plus Ganciclovir in Patients With AIDS and Cytomegalovirus (CMV) Infection
• The Safety and Effectiveness of FIAC in the Treatment of Cytomegalovirus (CMV) in Patients With AIDS
• A Study of Cidofovir in HIV-Infected Children With Cytomegalovirus (CMV) Disease
• A Pharmacokinetic and Tolerance Study of Oral Ganciclovir in HIV-Infected Children With Asymptomatic Cytomegalovirus Infection and Low CD4 Cell Counts or Quiescent Cytomegalovirus Disease
• Transfusion-Transmitted Cytomegalovirus Prevention in Neonates